Within the subset of breast cancer, they isolated the patients with the top 10% of TMB and demonstrated improved overall survival in this group as compared to the other 90% with a trend towards significance [ 18 ].
← all excerpts
Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Breast Cancer: Looking beyond Tumoral PD-L1.
1
—
—